1,543 Shares in Inspire Medical Systems, Inc. (NYSE:INSP) Acquired by Farringdon Capital Ltd.

Farringdon Capital Ltd. bought a new stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) in the fourth quarter, HoldingsChannel reports. The institutional investor bought 1,543 shares of the company’s stock, valued at approximately $286,000.

Other hedge funds have also made changes to their positions in the company. Zacks Investment Management raised its holdings in shares of Inspire Medical Systems by 12.7% in the fourth quarter. Zacks Investment Management now owns 12,657 shares of the company’s stock valued at $2,346,000 after acquiring an additional 1,429 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Inspire Medical Systems by 1,775.3% in the 4th quarter. Marshall Wace LLP now owns 277,131 shares of the company’s stock valued at $51,375,000 after purchasing an additional 262,353 shares in the last quarter. Guggenheim Capital LLC lifted its position in shares of Inspire Medical Systems by 28.6% in the 4th quarter. Guggenheim Capital LLC now owns 2,938 shares of the company’s stock worth $545,000 after purchasing an additional 654 shares during the period. XTX Topco Ltd bought a new position in shares of Inspire Medical Systems during the fourth quarter valued at approximately $459,000. Finally, Mariner LLC increased its holdings in Inspire Medical Systems by 1.6% during the fourth quarter. Mariner LLC now owns 4,837 shares of the company’s stock valued at $897,000 after buying an additional 77 shares during the period. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Inspire Medical Systems Price Performance

NYSE INSP opened at $150.42 on Friday. The company has a market cap of $4.48 billion, a price-to-earnings ratio of 86.95, a PEG ratio of 2.86 and a beta of 1.39. The stock’s fifty day moving average price is $166.16 and its 200 day moving average price is $183.40. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $257.40.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. Research analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Insider Buying and Selling at Inspire Medical Systems

In related news, CTO John Rondoni sold 583 shares of the firm’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total transaction of $99,395.67. Following the completion of the transaction, the chief technology officer now owns 10,424 shares of the company’s stock, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Randy Ban sold 25,584 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the completion of the sale, the insider now directly owns 7,259 shares in the company, valued at approximately $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Morgan Stanley dropped their target price on Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. Robert W. Baird cut their target price on Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 11th. Royal Bank of Canada decreased their price target on shares of Inspire Medical Systems from $260.00 to $215.00 and set an “outperform” rating for the company in a research report on Tuesday. Truist Financial lowered their price target on shares of Inspire Medical Systems from $250.00 to $235.00 and set a “buy” rating on the stock in a report on Tuesday, February 11th. Finally, Piper Sandler reduced their price objective on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $222.20.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.